Evaluating Tamsulosin hydrochloride (cas 106463-17-6)-released microparticles prepared using single-step matrix coating

Add time:07/30/2019    Source:sciencedirect.com

The objective of the present study was to determine the optimum composition for sustained-release of tamsulosin hydrochloride from microparticles intended for orally disintegrating tablets. Microparticles were prepared from an aqueous ethylcellulose dispersion (Aquacoat®), and an aqueous copolymer based on ethyl acrylate and methyl methacrylate dispersion (Eudragit® NE30D), with microcrystalline cellulose as core particles with a fluidized bed coating process. Prepared microparticles were about 200 μm diameter and spherical. The microparticles were evaluated for in vitro drug release and in vivo absorption to assess bioequivalence in a commercial product, Harnal® pellets. The optimum ratio of Aquacoat® and Eudragit® NE30D in the matrix was 9:1. We observed similar drug release profiles in microparticles and Harnal® pellets. Higuchi model analysis of the in vitro drug release from microparticles was linear up to 80% release, typical of Fickian diffusion sustained-release profile. The in vivo absorption properties from microparticles were comparable to Harnal® pellets, and there was a linear relationship between in vitro drug release and in vivo drug release. In conclusion, this development produces microparticles in single-step coating, that provided a sustained-release of tamsulosin hydrochloride comparable to Harnal® pellets.

We also recommend Trading Suppliers and Manufacturers of Tamsulosin hydrochloride (cas 106463-17-6). Pls Click Website Link as below: cas 106463-17-6 suppliers

Prev:Pharmacokinetic Interaction of Finasteride With Tamsulosin hydrochloride (cas 106463-17-6): An Open-label, Randomized, 3-period Crossover Study in Healthy Chinese Male Volunteers
Next:Spectrophotometric estimation of Tamsulosin hydrochloride (cas 106463-17-6) by acid-dye method)